Invivyd (NASDAQ:IVVD) Given Buy Rating at D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $9.00 target price on the stock.

IVVD has been the subject of several other research reports. HC Wainwright dropped their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Stock Down 2.1 %

IVVD opened at $0.45 on Friday. The firm has a 50-day simple moving average of $0.64 and a two-hundred day simple moving average of $0.91. Invivyd has a 52 week low of $0.40 and a 52 week high of $5.20. The company has a market capitalization of $54.07 million, a PE ratio of -0.23 and a beta of 0.64.

Insider Activity at Invivyd

In related news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the transaction, the director now owns 4,538,079 shares of the company’s stock, valued at approximately $2,768,228.19. This trade represents a 3.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 816,466 shares of company stock valued at $423,214. Insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IVVD. Proficio Capital Partners LLC bought a new stake in Invivyd in the third quarter worth about $27,000. XTX Topco Ltd lifted its stake in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. bought a new stake in Invivyd in the second quarter worth about $86,000. Rhumbline Advisers lifted its stake in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Invivyd in the second quarter worth about $115,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.